SCHEMBL2269499

SCHEMBL2269499

CC1CC(CO)CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17042948 1.00
SCHEMBL17042949 1.00
SCHEMBL17047993 1.00
SCHEMBL17043001 1.00
SCHEMBL17042046 1.00
Hydrochloric Acid SCHEMBL3609098 0.98
Hydrochloric Acid SCHEMBL3607849 0.98
Hydrochloric Acid SCHEMBL3607842 0.98
Hydrochloric Acid SCHEMBL3607844 0.98
Hydrochloric Acid SCHEMBL3609103 0.98

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-12-21 US disclosed
WO-2023122945-A1 CYCLIC POLYPEPTIDE COMPOUNDS AND USES THEREOF 知和(山东)大药厂有限公司 2023-07-06 WO disclosed
EP-3998267-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Bellus Health Cough Inc. (CA) 2022-05-18 EP disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 US disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 US disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 EP disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 EP disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 US disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 US disclosed
CN-107485612-B Imidazopyridine compounds and uses thereof 尼奥迈德研究所 2021-03-30 CN disclosed
US-8357709-B2 2,4-disubstituted pyrrolidine orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2013-01-22 US disclosed
US-20110201652-A1 2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists MERCK SHARP & DOHME LLC 2011-08-18 US disclosed
US-20110201652-A1 2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists MERCK SHARP & DOHME LLC 2011-08-18 US disclosed
US-20110201652-A1 2,4-Disubstituted Pyrrolidine Orexin Receptor Antagonists MERCK SHARP & DOHME LLC 2011-08-18 US disclosed
EP-2348856-A1 2,4-DISUBSTITUTED PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2011-08-03 EP disclosed
WO-2010048014-A1 2,4-DISUBSTITUTED PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 WO disclosed
WO-2010048014-A1 2,4-DISUBSTITUTED PYRROLIDINE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2010-04-29 WO disclosed
US-7649001-B2 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-19 US disclosed
US-20090042857-A1 Novel Pharmaceutical TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-12 US disclosed
EP-1987827-A1 NOVEL PHARMACEUTICAL Takeda Pharmaceutical Company Limited (JP) 2008-11-05 EP disclosed